Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference. Management will provide an overview of the company’s experience and expertise in the autoimmune and inflammatory disease space and highlight EQ101, a tr
Click here to view original post